Switch theme
Sign up to access all valuation multiples
APT Medical Inc is engaged in the research and development, production and sales of electrophysiological and vascular interventional medical devices for cardiovascular and cerebrovascular diseases. Its products are sold in Europe, Eastern Europe, Southeast Asia and other countries and other regions.
2002
n/a
LTM Revenue $323M
LTM EBITDA $130M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
APT Medical has a last 12-month revenue (LTM) of $323M and a last 12-month EBITDA of $130M.
In the most recent fiscal year, APT Medical achieved revenue of $287M and an EBITDA of $116M.
APT Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See APT Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $323M | XXX | $287M | XXX | XXX | XXX |
| Gross Profit | $234M | XXX | $207M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $130M | XXX | $116M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBIT | $119M | XXX | $105M | XXX | XXX | XXX |
| EBIT Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| Net Profit | $106M | XXX | $93.4M | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, APT Medical's stock price is CNY 397 (or $55).
APT Medical has current market cap of CNY 38.5B (or $5.3B), and EV of CNY 37.3B (or $5.2B).
See APT Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $5.3B | XXX | XXX | XXX | XXX | $1.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, APT Medical has market cap of $5.3B and EV of $5.2B.
APT Medical's trades at 18.1x EV/Revenue multiple, and 44.7x EV/EBITDA.
Equity research analysts estimate APT Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
APT Medical has a P/E ratio of 50.3x.
See valuation multiples for APT Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 16.0x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBITDA | 39.7x | XXX | 44.7x | XXX | XXX | XXX |
| EV/EBIT | 43.4x | XXX | 49.4x | XXX | XXX | XXX |
| EV/Gross Profit | 22.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 50.3x | XXX | 57.2x | XXX | XXX | XXX |
| EV/FCF | 179.1x | XXX | 400.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAPT Medical's last 12 month revenue growth is 30%
APT Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
APT Medical's rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
APT Medical's rule of X is 115% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for APT Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | 70% | XXX | 70% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 115% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
APT Medical acquired XXX companies to date.
Last acquisition by APT Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . APT Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was APT Medical founded? | APT Medical was founded in 2002. |
| Where is APT Medical headquartered? | APT Medical is headquartered in China. |
| Is APT Medical publicy listed? | Yes, APT Medical is a public company listed on SHG. |
| What is the stock symbol of APT Medical? | APT Medical trades under 688617 ticker. |
| When did APT Medical go public? | APT Medical went public in 2021. |
| Who are competitors of APT Medical? | Similar companies to APT Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of APT Medical? | APT Medical's current market cap is $5.3B |
| What is the current revenue of APT Medical? | APT Medical's last 12 months revenue is $323M. |
| What is the current revenue growth of APT Medical? | APT Medical revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of APT Medical? | Current revenue multiple of APT Medical is 16.0x. |
| Is APT Medical profitable? | Yes, APT Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of APT Medical? | APT Medical's last 12 months EBITDA is $130M. |
| What is APT Medical's EBITDA margin? | APT Medical's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of APT Medical? | Current EBITDA multiple of APT Medical is 39.7x. |
| What is the current FCF of APT Medical? | APT Medical's last 12 months FCF is $28.9M. |
| What is APT Medical's FCF margin? | APT Medical's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of APT Medical? | Current FCF multiple of APT Medical is 179.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
